This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Global Anticoagulants Industry

NEW YORK, Dec. 5, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Global Anticoagulants Industry

http://www.reportlinker.com/p098261/Global-Anticoagulants-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

 

This report analyzes the worldwide markets for Anticoagulants in Millions of US$ by the following Product Segments: Oral Anticoagulants, and Injectable Anticoagulants (Unfractionated Heparin, and Low Molecular Weight Heparin). The report provides separate comprehensive analytics for the US, Japan, Europe and Rest of World. Annual estimates and forecastsare provided for the period of 2010 through 2018. A six-year historic analysis is also provided for these markets. The report profiles 45 companies including many key and niche players such as Bayer Healthcare AG, Boehringer Ingelheim, Bristol-Myers Squibb Company, Eisai Inc., GlaxoSmithKline plc, LEO Pharmaceutical Products, Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., and Sanofi, Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

 

 

 

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-2

Quantitative Techniques & Analytics I-2

Product Definitions And Scope of Study I-3

 

 

II. EXECUTIVE SUMMARY

 

1. OUTLOOK II-1

A Prelude II-1

Anticoagulants- An Evolving Market II-1

Injectables or Oral Drugs - The Road Ahead II-2

Conventional Oral Drugs to Face the Heat Too II-2

New Drugs yet to Gain Mainstream Status II-2

Sizing the Market II-3

 

2. INDUSTRY OVERVIEW II-4

Issues with Traditional Drugs Fueling the Hunt for New

Anticoagulants II-4

New Therapies: Need of the Hour II-4

Drug Advancements Drive Anticoagulant Market II-4

Niche Markets - The New Target for Drug Makers II-4

1 of 15

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs